Kinase Inhibitors Can Inhibit SARS-CoV-2 Mpro: A Theoretical Study

26 August 2020, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

This study describes screening of DrugBank library for approved drugs by pharmacophore modeling and receptor-ligand docking. A 3D-QSAR model was generated on the
inhibition constants (Ki AutoDock ) determined by AutoDock. This 3D-QSAR model was statistically validated by Fischer’s randomization test and further evaluated by a test set
comprising 75 molecules. Ki AutoDock values of 49 molecules were predicted correctly by the 3D-QSAR model. The validated 3D-QSAR model was used for screening of DrugBank library for approved molecules to identify potential molecules against novel SARS corona virus-2 (SARS-CoV-2). Ten out of 40 the shortlisted molecules were kinase inhibitors.

Keywords

pharmacophore model
Covid-19
M proteins
Docking
kinase inhibitors erlotinib

Supplementary materials

Title
Description
Actions
Title
Supplementary Materials
Description
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.